Quinupristin/Dalfopristin

奎奴普丁/达福普汀

Report date: 2026/03/04 20:01:44
NME

Base Information

Drug NameQuinupristin/Dalfopristin
Drug Alias Name达福普汀/奎奴普丁Quinupristin - dalfopristin达福普丁+奎奴普丁Dalfopristin/Quinupristinquinupristin and dalfopristin +[8] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Macrolides antibioticsSmall molecules > Synthetic peptide
Mechanisms of Action50S ribosomal subunit inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsComplicated Skin and Soft Tissue InfectionsEnterococcus faecium infectionsAcute bacterial skin and skin structure infections +[6] 
Global Approved IndicationsComplicated Skin and Soft Tissue InfectionsEnterococcus faecium infectionsAcute bacterial skin and skin structure infections +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1999/07/29
Country/TerritoryUnited StatesUnited KingdomJapan
CombinationsYes Quinupristin mesilate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer IncSanofi
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncKing Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsAcute bacterial skin and skin structure infectionsBacteremiaBacterial Infections
Inactive IndicationsComplicated Skin and Soft Tissue InfectionsEnterococcus faecium infectionsGram-Positive Bacterial Infections

Other Information

ATC CodeJ01FG02
Related LinksWikipediaKEGG